CClinicalTrials.gg
CompletedNCT02864966Updated Sep 9, 2016

A 24 Hour Occlusive Single Patch Test to Assess Acute Tolerance of Pre Lubricated Condom on a Panel of Healthy Adult Subjects

An interventional study of Condom in Healthy, sponsored by Reckitt Benckiser Healthcare (UK) Limited. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-09-09.

Sponsored by Reckitt Benckiser Healthcare (UK) Limited · Not applicable and Interventional

Phase
Not applicable
Study type
Interventional
Enrollment
33
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This is a 24 hour patch test to determine the acute tolerance of 3 variants of condom on a panel of healthy adult subjects. The patches will be affixed to the back and remain under occlusion for 24 hours. They will then be assessed at 30 minutes and 24 hours post patch removal.

Read the detailed description

Three test products (plus positive and negative control) will be applied to the back using occlusive tape and will remain on the skin for 24 hours. The patches will be removed after 24 hours and assessed as 30 minutes post patch removal and again at 24 hours post patch removal. Each test site will be scored for erythema and oedema by a dermatologist.

The primary endpoint for this Clinical Investigation is the irritation of the test products according to the Cutaneous Irritancy Index value. The test products success criteria is to be graded as 'non-irritant' and this should be confirmed by the study dermatologist.

02

Conditions studied

  • Healthy

Keywords

  • Safety study
  • new product
  • normal healthy skin.
03

In context

Lead sponsor

Reckitt Benckiser Healthcare (UK) Limited is the lead sponsor of 34 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Subjects who are able to give written informed consent and from whom written informed consent has been obtained
  • Generally healthy male or female subjects between the ages of 18 and 70 years inclusive.
  • Subjects assessed by the dermatologist as having normal/healthy skin.
  • Subjects with skin Phototype I to IV skin.
  • Subjects who have been exposed to Natural Rubber Latex through condom use with no allergic reaction being raised
  • Subjects, who are able to understand the study, co-operate with the study procedures (including no swimming during the study period) and are able to attend all study assessments.

Exclusion criteria

Exclusion Criteria:

  • Female subjects who are pregnant, lactating or have given birth within the previous 3 months or are planning to be pregnant during the study.
  • Female subjects of childbearing potential who, for the duration of the study, are either unwilling or unable to take adequate contraceptive precautions or are unwilling to be sexually abstinent.
  • Subjects with previous experience of intolerance or allergic reactions to any components of the test products including latex and lubricants.
  • Subjects with either form of diabetes.
  • Subjects with an active skin disorder or a significant history of skin disorders (e.g. psoriasis, eczema, vitiligo, pityriasis versicolor, acne) which in the opinion of the Principle Investigator or dermatologist may affect the test results
  • Subjects whose skin has been excessively exposed to the sun or to UV rays during the previous month in the opinion of the Investigator.
  • Subjects who are suffering from chronic asthma, a malfunction of the lymphatic system or an autoimmune deficiency diseases (e.g. lupus, thyroiditis).
  • Subjects with very easily irritated/sensitive skin in the opinion of the Investigator.
05

Study design

Phase
Not applicable
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Other
    Other

    This is a safety study where a marketed product will be placed on healthy adult skin.

    Device: Condom

Interventions

  • DeviceCondom

    This study involves testing a condom, however the device will not be used as intended. The device will be destroyed to make the test patches required for this safety study.

    Also known as: Durex

06

What researchers measure

Primary outcomes

  1. The primary endpoint is the irritation of the test products according to the Cutaneous Irritancy Index value. The test products are expected to be graded as 'non-irritant' as confirmed by a dermatologist.

    Acute tolerance study to test the safety of a new condom on healthy adult skin.

    Time frame: 24 hours

07

Study locations

1 site
  • Alba Science Ltd
    Edinburgh, EH1 3RH, United Kingdom
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 9, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02864966
Lead sponsor
Reckitt Benckiser Healthcare (UK) Limited
Collaborators
Alba Science Ltd
Responsible party
Sponsor
First posted
Aug 12, 2016
Start date
May 2016
Primary completion
May 2016
Completion
May 2016
Last update
Sep 9, 2016

Study contacts

Marie Reynolds
principal investigator · Alba Science Ltd

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion